Please ensure Javascript is enabled for purposes of website accessibility

Laurels, Shmaurels, Let's Grow

By Brian Orelli, PhD - Updated Apr 5, 2017 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

SonoSite produces another impressive quarter.

You've got to love a company with a CEO who says, "There's still a lot of work to be done," in an earnings conference call where year-over-year revenue grew 24%. Talk about not resting on your laurels.

It wasn't just hand-held ultrasound maker SonoSite's (NASDAQ:SONO) top line that grew, its bottom line continued to see substantial growth as the company gets more efficient, with net income up more than 300%.

Gross margins continued to slip as the company sells a larger numbers of units to international distributors at a discount. But international sales have fewer marketing costs, so the company was able to lower sales, general and administrative (SG&A) expenses by 300 basis points.

That increased efficiency is pretty impressive given the increased legal costs that SonoSite is incurring as it gears up for two patent litigation cases -- with Zonare Medical Systems and General Electric (NYSE:GE) -- next year. If it can win those lawsuits and reap royalties from its competitors' products, the money certainly will be well spent.

SonoSite is guiding revenue growth of at least 15% for next year, which shouldn't be too tough given its launch of five new products this month. The company is trying to expand the market by offering a wide variety of price points for hospitals as well as doctors' offices. It's moving away from the Swiss Army style machine to more specialized machines for specific applications. Four of the five instruments it launched are of this style, although they're all based on the same platform using Texas Instruments' (NYSE:TXN) DaVinci technology and Microsoft's (NASDAQ:MSFT) Windows CE.

Management hinted that they're interested in making an acquisition, but didn't give much other information. They certainly need to find something to do with the $309 million in cash and investments the company has on the books. The cash flow machine is going to continue to churn for many quarters to come.

More Foolishness about medical devices:

The Fool's market-beating Rule Breakers newsletter has picked three medical device companies including SonoSite. Click here to find out the other two, and take a look at all our recommendations with a free 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Microsoft is a selection of the Inside Value newsletter. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

FUJIFILM SonoSite, Inc. Stock Quote
FUJIFILM SonoSite, Inc.
SONO
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$292.71 (-0.26%) $0.76
General Electric Company Stock Quote
General Electric Company
GE
$81.07 (1.58%) $1.26
Texas Instruments Incorporated Stock Quote
Texas Instruments Incorporated
TXN
$183.36 (-1.10%) $-2.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.